These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 39372417)

  • 21. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.
    Abdelnabi MN; Hassan GS; Shoukry NH
    Front Immunol; 2024; 15():1437046. PubMed ID: 39156888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Egr2 drives the differentiation of Ly6C
    Iwata A; Maruyama J; Natsuki S; Nishiyama A; Tamura T; Tanaka M; Shichino S; Seki T; Komai T; Okamura T; Fujio K; Tanaka M; Asano K
    Commun Biol; 2024 Jun; 7(1):681. PubMed ID: 38831027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.
    Mori T; Yoshio S; Kakazu E; Kanto T
    Gastroenterol Rep (Oxf); 2024; 12():goae089. PubMed ID: 39411101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Popov J; Despot T; Avelar Rodriguez D; Khan I; Mech E; Khan M; Bojadzija M; Pai N
    Nutrients; 2024 May; 16(11):. PubMed ID: 38892602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incretin-based investigational therapies for the treatment of MASLD/MASH.
    Brouwers B; Rao G; Tang Y; Rodríguez Á; Glass LC; Hartman ML
    Diabetes Res Clin Pract; 2024 May; 211():111675. PubMed ID: 38636848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intricate interplay between cell metabolism and necroptosis regulation in metabolic dysfunction-associated steatotic liver disease: A narrative review.
    Afonso MB; David JC; Alves MI; Santos AA; Campino G; Ratziu V; Gautheron J; Rodrigues CMP
    Metabolism; 2024 Sep; 158():155975. PubMed ID: 39004396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes.
    Younossi ZM; Golabi P; Price JK; Owrangi S; Gundu-Rao N; Satchi R; Paik JM
    Clin Gastroenterol Hepatol; 2024 Oct; 22(10):1999-2010.e8. PubMed ID: 38521116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ACMSD inhibition corrects fibrosis, inflammation, and DNA damage in MASLD/MASH.
    Liu YJ; Kimura M; Li X; Sulc J; Wang Q; Rodríguez-López S; Scantlebery AML; Strotjohann K; Gallart-Ayala H; Vijayakumar A; Myers RP; Ivanisevic J; Houtkooper RH; Subramanian GM; Takebe T; Auwerx J
    J Hepatol; 2024 Aug; ():. PubMed ID: 39181211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD).
    Lopez-Pascual A; Russo-Cabrera JS; Ardaiz N; Palmer T; Graham AR; Uriarte I; Gomar C; Ruiz-Guillamon D; Latasa MU; Arechederra M; Fontanellas A; Monte MJ; Marin JJG; Berasain C; Del Rio CL; Fernandez-Barrena MG; Martini PGV; Schultz JR; Berraondo P; Avila MA
    Clin Sci (Lond); 2024 Oct; 138(20):1265-1284. PubMed ID: 39301694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.